Last 12 months
Inside the activity.
0 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2023 Filed Feb 10, 2023 23:36 UTC |
Herbert Timothy P.Director · CEO and President
|
SaleCommon Stock | 7,028 | $275.12 | $1,933,543.36 |
DisclosureSEC source: 0001104659-23-018715 · tm236006-2_4seq1.xml · nonDerivative · entry 3 Herbert Timothy P. · CIK 0001737136 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 12,347 F2 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.00 to $275.61, inclusive. The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Shares held by the Margaret C. Herbert 2018 Family Irrevocable GST Trust. Read SEC document |
| February 08, 2023 Filed Feb 8, 2023 22:12 UTC |
Rondoni JohnChief Technology Officer
|
SaleCommon Stock | 1,560 | $270.00 | $421,200.00 |
DisclosureSEC source: 0001104659-23-014611 · tm236006-1_4seq1.xml · nonDerivative · entry 6 Rondoni John · CIK 0001932219 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,091 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 08, 2023 Filed Feb 8, 2023 22:12 UTC |
Rondoni JohnChief Technology Officer
|
SaleCommon Stock | 940 | $265.00 | $249,100.00 |
DisclosureSEC source: 0001104659-23-014611 · tm236006-1_4seq1.xml · nonDerivative · entry 5 Rondoni John · CIK 0001932219 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,651 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 23:36 UTC |
Herbert Timothy P.Director · CEO and President
|
SaleCommon Stock | 3,500 | $275.00 | $962,500.00 |
DisclosureSEC source: 0001104659-23-018715 · tm236006-2_4seq1.xml · nonDerivative · entry 2 Herbert Timothy P. · CIK 0001737136 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 19,375 F2 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · ownership.nature: Shares held by the Margaret C. Herbert 2018 Family Irrevocable GST Trust. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 22:12 UTC |
Rondoni JohnChief Technology Officer
|
SaleCommon Stock | 361 | $251.72 | $90,870.92 |
DisclosureSEC source: 0001104659-23-014611 · tm236006-1_4seq1.xml · nonDerivative · entry 4 Rondoni John · CIK 0001932219 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,591 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $251.42 to $252.06, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 22:12 UTC |
Rondoni JohnChief Technology Officer
|
SaleCommon Stock | 949 | $250.73 | $237,942.77 |
DisclosureSEC source: 0001104659-23-014611 · tm236006-1_4seq1.xml · nonDerivative · entry 3 Rondoni John · CIK 0001932219 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,952 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $250.42 to $251.34, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 22:12 UTC |
Rondoni JohnChief Technology Officer
|
SaleCommon Stock | 1,700 | $249.91 | $424,847.00 |
DisclosureSEC source: 0001104659-23-014611 · tm236006-1_4seq1.xml · nonDerivative · entry 2 Rondoni John · CIK 0001932219 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,901 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $249.41 to $250.40, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 22:12 UTC |
Rondoni JohnChief Technology Officer
|
SaleCommon Stock | 490 | $249.08 | $122,049.20 |
DisclosureSEC source: 0001104659-23-014611 · tm236006-1_4seq1.xml · nonDerivative · entry 1 Rondoni John · CIK 0001932219 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,601 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $248.34 to $249.28, inclusive. The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 29, 2023 Filed Feb 1, 2023 00:15 UTC |
Phillips Bryan KSee Remarks
|
Tax withholdingCommon Stock | 205 | $253.24 | $51,914.20 |
DisclosureSEC source: 0001104659-23-008812 · tm235077-1_4seq1.xml · nonDerivative · entry 1 Phillips Bryan K · CIK 0001412895 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,960 F1 · shares: Reflects shares of common stock that were withheld by the Issuer to satisfy taxes incident to vesting of a restricted stock unit award. F2 · balance_after: Includes (i) 48 shares acquired under the Inspire Medical Systems, Inc. (the "Company") 2018 Employee Stock Purchase Plan (the "Plan") on June 30, 2022 and (ii) 47 shares acquired under the Company Plan on December 31, 2022. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 01:00 UTC |
Buchholz RichardChief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,693 | $0.00 Strike: $42.15 | $0.00 |
DisclosureSEC source: 0001104659-23-007634 · tm234399-2_4seq1.xml · derivative · entry 10 Buchholz Richard · CIK 0001737133 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,159 Underlying: Common Stock · 2,693 shares Expires 2028-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 01:00 UTC |
Buchholz RichardChief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 117 | $0.00 Strike: $71.00 | $0.00 |
DisclosureSEC source: 0001104659-23-007634 · tm234399-2_4seq1.xml · derivative · entry 9 Buchholz Richard · CIK 0001737133 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,849 Underlying: Common Stock · 117 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested and became exercisable as to 25% of the original 20,000 underlying shares on December 16, 2020 and has vested or will vest and become exercisable with respect to the remaining 75% of the original underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 01:00 UTC |
Buchholz RichardChief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,290 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001104659-23-007634 · tm234399-2_4seq1.xml · derivative · entry 8 Buchholz Richard · CIK 0001737133 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,290 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 01:00 UTC |
Buchholz RichardChief Financial Officer
|
Exercise / conversionCommon Stock | 2,693 | $42.15 | $113,509.95 |
DisclosureSEC source: 0001104659-23-007634 · tm234399-2_4seq1.xml · nonDerivative · entry 3 Buchholz Richard · CIK 0001737133 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 01:00 UTC |
Buchholz RichardChief Financial Officer
|
Exercise / conversionCommon Stock | 117 | $71.00 | $8,307.00 |
DisclosureSEC source: 0001104659-23-007634 · tm234399-2_4seq1.xml · nonDerivative · entry 2 Buchholz Richard · CIK 0001737133 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 01:00 UTC |
Buchholz RichardChief Financial Officer
|
Exercise / conversionCommon Stock | 3,290 | $10.38 | $34,150.20 |
DisclosureSEC source: 0001104659-23-007634 · tm234399-2_4seq1.xml · nonDerivative · entry 1 Buchholz Richard · CIK 0001737133 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 21:05 UTC |
Jandrich StevenVP, Human Resources
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 500 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001104659-23-006533 · tm234399-1_4seq1.xml · derivative · entry 4 Jandrich Steven · CIK 0001737203 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,825 Underlying: Common Stock · 500 shares Expires 2027-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 21:05 UTC |
Jandrich StevenVP, Human Resources
|
Exercise / conversionCommon Stock | 500 | $0.94 | $470.00 |
DisclosureSEC source: 0001104659-23-006533 · tm234399-1_4seq1.xml · nonDerivative · entry 1 Jandrich Steven · CIK 0001737203 · VP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2023 Filed Jan 13, 2023 21:59 UTC |
Buchholz RichardChief Financial Officer
|
SaleCommon Stock | 11,977 | $250.03 | $2,994,609.31 |
DisclosureSEC source: 0001104659-23-003858 · tm233471-1_4seq1.xml · nonDerivative · entry 7 Buchholz Richard · CIK 0001737133 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,387 F2 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $250.00 to $250.25, inclusive. The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 21:59 UTC |
Buchholz RichardChief Financial Officer
|
SaleCommon Stock | 523 | $250.00 | $130,750.00 |
DisclosureSEC source: 0001104659-23-003858 · tm233471-1_4seq1.xml · nonDerivative · entry 6 Buchholz Richard · CIK 0001737133 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,364 F2 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 10, 2023 Filed Jan 20, 2023 00:56 UTC |
Melenikiotou GeorgiaDirector
|
GrantCommon Stock | 55 | $248.31 | $13,657.05 |
DisclosureSEC source: 0001104659-23-005114 · tm233800-4_4.xml · nonDerivative · entry 1 Melenikiotou Georgia · CIK 0001817552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| January 10, 2023 Filed Jan 20, 2023 00:58 UTC |
NELSON MARILYN CDirector
|
GrantCommon Stock | 85 | $248.31 | $21,106.35 |
DisclosureSEC source: 0001104659-23-005116 · tm233800-6_4seq1.xml · nonDerivative · entry 1 NELSON MARILYN C · CIK 0001199894 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,134 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| January 10, 2023 Filed Jan 20, 2023 00:57 UTC |
Broader Shelley GDirector
|
GrantCommon Stock | 60 | $248.31 | $14,898.60 |
DisclosureSEC source: 0001104659-23-005115 · tm233800-5_4seq1.xml · nonDerivative · entry 1 Broader Shelley G. · CIK 0001426843 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| January 10, 2023 Filed Jan 20, 2023 00:55 UTC |
Ellis Gary LeeDirector
|
GrantCommon Stock | 60 | $248.31 | $14,898.60 |
DisclosureSEC source: 0001104659-23-005113 · tm233800-3_4seq1.xml · nonDerivative · entry 1 Ellis Gary Lee · CIK 0001290170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,259 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| January 10, 2023 Filed Jan 20, 2023 00:54 UTC |
Sparks Charisse YDirector
|
GrantCommon Stock | 52 | $248.31 | $12,912.12 |
DisclosureSEC source: 0001104659-23-005112 · tm233800-2_4seq1.xml · nonDerivative · entry 1 Sparks Charisse Y · CIK 0001940873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| January 10, 2023 Filed Jan 20, 2023 00:53 UTC |
Tansey Casey MDirector
|
GrantCommon Stock | 52 | $248.31 | $12,912.12 |
DisclosureSEC source: 0001104659-23-005111 · tm233800-1_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,543 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy. Read SEC document |
| January 05, 2023 Filed Jan 13, 2023 21:59 UTC |
Buchholz RichardChief Financial Officer
|
GiftCommon Stock | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-003858 · tm233471-1_4seq1.xml · nonDerivative · entry 5 Buchholz Richard · CIK 0001737133 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Son Disclosed balance after: 1,225 Read SEC document |
| January 05, 2023 Filed Jan 13, 2023 21:59 UTC |
Buchholz RichardChief Financial Officer
|
GiftCommon Stock | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-003858 · tm233471-1_4seq1.xml · nonDerivative · entry 4 Buchholz Richard · CIK 0001737133 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Son Disclosed balance after: 1,225 Read SEC document |
| January 05, 2023 Filed Jan 13, 2023 21:59 UTC |
Buchholz RichardChief Financial Officer
|
GiftCommon Stock | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-003858 · tm233471-1_4seq1.xml · nonDerivative · entry 3 Buchholz Richard · CIK 0001737133 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Son Disclosed balance after: 1,225 Read SEC document |
| January 05, 2023 Filed Jan 13, 2023 21:59 UTC |
Buchholz RichardChief Financial Officer
|
GiftCommon Stock | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-003858 · tm233471-1_4seq1.xml · nonDerivative · entry 2 Buchholz Richard · CIK 0001737133 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Daughter Disclosed balance after: 1,225 Read SEC document |
| January 05, 2023 Filed Jan 13, 2023 21:59 UTC |
Buchholz RichardChief Financial Officer
|
GiftCommon Stock | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-003858 · tm233471-1_4seq1.xml · nonDerivative · entry 1 Buchholz Richard · CIK 0001737133 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,887 F1 · balance_after: Includes (i) 80 shares acquired under the Inspire Medical Systems, Inc. (the "Company") 2018 Employee Stock Purchase Plan (the "Plan") on June 30, 2022 and (ii) 31 shares acquired under the Company Plan on December 31, 2022. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 00:01 UTC |
Ban RandyChief Commercial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001104659-23-001570 · tm232257-1_4seq1.xml · derivative · entry 9 Ban Randy · CIK 0001737127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,090 Underlying: Common Stock · 10,000 shares Expires 2027-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 00:01 UTC |
Ban RandyChief Commercial Officer
|
SaleCommon Stock | 156 | $255.98 | $39,932.88 |
DisclosureSEC source: 0001104659-23-001570 · tm232257-1_4seq1.xml · nonDerivative · entry 6 Ban Randy · CIK 0001737127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304 F2 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $255.97 to $256.00, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 00:01 UTC |
Ban RandyChief Commercial Officer
|
SaleCommon Stock | 1,056 | $253.79 | $268,002.24 |
DisclosureSEC source: 0001104659-23-001570 · tm232257-1_4seq1.xml · nonDerivative · entry 5 Ban Randy · CIK 0001737127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460 F2 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $253.41 to $254.2966, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 00:01 UTC |
Ban RandyChief Commercial Officer
|
SaleCommon Stock | 3,788 | $252.71 | $957,265.48 |
DisclosureSEC source: 0001104659-23-001570 · tm232257-1_4seq1.xml · nonDerivative · entry 4 Ban Randy · CIK 0001737127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,516 F2 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $252.26 to $253.16, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 00:01 UTC |
Ban RandyChief Commercial Officer
|
SaleCommon Stock | 2,600 | $251.64 | $654,264.00 |
DisclosureSEC source: 0001104659-23-001570 · tm232257-1_4seq1.xml · nonDerivative · entry 3 Ban Randy · CIK 0001737127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,304 F2 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $251.22 to $252.15, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 00:01 UTC |
Ban RandyChief Commercial Officer
|
SaleCommon Stock | 2,400 | $250.62 | $601,488.00 |
DisclosureSEC source: 0001104659-23-001570 · tm232257-1_4seq1.xml · nonDerivative · entry 2 Ban Randy · CIK 0001737127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,904 F2 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $250.09 to $251.05, inclusive. F4 · price: The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 00:01 UTC |
Ban RandyChief Commercial Officer
|
Exercise / conversionCommon Stock | 10,000 | $0.94 | $9,400.00 |
DisclosureSEC source: 0001104659-23-001570 · tm232257-1_4seq1.xml · nonDerivative · entry 1 Ban Randy · CIK 0001737127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 19 additional shares acquired under the Inspire Medical Systems, Inc. 2018 Employee Stock Purchase Plan since the Reporting Person's ownership report filed on December 6, 2022. Read SEC document |
| January 03, 2023 Filed Jan 10, 2023 02:20 UTC |
Rondoni JohnChief Technology Officer
|
SaleCommon Stock | 1,170 | $256.00 | $299,520.00 |
DisclosureSEC source: 0001104659-23-002388 · tm232886-1_4seq1.xml · nonDerivative · entry 1 Rondoni John · CIK 0001932219 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,091 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 31 additional shares acquired under the Inspire Medical Systems, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:05 UTC |
Rondoni JohnChief Technology Officer
|
SaleCommon Stock | 678 | $251.72 | $170,666.16 |
DisclosureSEC source: 0001104659-22-129082 · tm2233229-1_4seq1.xml · nonDerivative · entry 1 Rondoni John · CIK 0001932219 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,230 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 80 additional shares acquired under the Inspire Medical Systems, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:43 UTC |
NELSON MARILYN CDirector
|
SaleCommon Stock | 5,211 | $250.00 | $1,302,750.00 |
DisclosureSEC source: 0001104659-22-128720 · tm2233015-1_4seq1.xml · nonDerivative · entry 5 NELSON MARILYN C · CIK 0001199894 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 50,919 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · ownership.nature: Shares held by GDN Holdings, LLC, of which the Reporting Person is the managing member. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:43 UTC |
NELSON MARILYN CDirector
|
SaleCommon Stock | 1,662 | $248.00 | $412,176.00 |
DisclosureSEC source: 0001104659-22-128720 · tm2233015-1_4seq1.xml · nonDerivative · entry 4 NELSON MARILYN C · CIK 0001199894 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 56,130 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · ownership.nature: Shares held by GDN Holdings, LLC, of which the Reporting Person is the managing member. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:43 UTC |
NELSON MARILYN CDirector
|
SaleCommon Stock | 15,058 | $243.50 | $3,666,623.00 |
DisclosureSEC source: 0001104659-22-128720 · tm2233015-1_4seq1.xml · nonDerivative · entry 3 NELSON MARILYN C · CIK 0001199894 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 57,792 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.90 to $243.50, inclusive. F4 · ownership.nature: Shares held by GDN Holdings, LLC, of which the Reporting Person is the managing member. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:43 UTC |
NELSON MARILYN CDirector
|
SaleCommon Stock | 1,247 | $241.63 | $301,312.61 |
DisclosureSEC source: 0001104659-22-128720 · tm2233015-1_4seq1.xml · nonDerivative · entry 2 NELSON MARILYN C · CIK 0001199894 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 72,850 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $241.39 to $242.22, inclusive. F4 · ownership.nature: Shares held by GDN Holdings, LLC, of which the Reporting Person is the managing member. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:43 UTC |
NELSON MARILYN CDirector
|
SaleCommon Stock | 2,033 | $240.03 | $487,980.99 |
DisclosureSEC source: 0001104659-22-128720 · tm2233015-1_4seq1.xml · nonDerivative · entry 1 NELSON MARILYN C · CIK 0001199894 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 74,097 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.00 to $240.25, inclusive. F3 · price: The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: Shares held by GDN Holdings, LLC, of which the Reporting Person is the managing member. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 21:15 UTC |
Ban RandyChief Commercial Officer
|
SaleCommon Stock | 1,149 | $239.16 | $274,794.84 |
DisclosureSEC source: 0001104659-22-124890 · tm2232063d1_4seq1.xml · nonDerivative · entry 6 Ban Randy · CIK 0001737127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285 F2 · shares: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $238.66 to $239.60. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 21:15 UTC |
Ban RandyChief Commercial Officer
|
SaleCommon Stock | 1,400 | $238.05 | $333,270.00 |
DisclosureSEC source: 0001104659-22-124890 · tm2232063d1_4seq1.xml · nonDerivative · entry 5 Ban Randy · CIK 0001737127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,434 F2 · shares: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $237.60 to $238.54. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 21:15 UTC |
Ban RandyChief Commercial Officer
|
SaleCommon Stock | 642 | $236.64 | $151,922.88 |
DisclosureSEC source: 0001104659-22-124890 · tm2232063d1_4seq1.xml · nonDerivative · entry 4 Ban Randy · CIK 0001737127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,834 F2 · shares: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $236.24 to $237.21. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 21:15 UTC |
Ban RandyChief Commercial Officer
|
SaleCommon Stock | 1,954 | $235.29 | $459,756.66 |
DisclosureSEC source: 0001104659-22-124890 · tm2232063d1_4seq1.xml · nonDerivative · entry 3 Ban Randy · CIK 0001737127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,476 F2 · shares: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.11 to $236.24. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 21:15 UTC |
Ban RandyChief Commercial Officer
|
SaleCommon Stock | 5,188 | $234.68 | $1,217,519.84 |
DisclosureSEC source: 0001104659-22-124890 · tm2232063d1_4seq1.xml · nonDerivative · entry 2 Ban Randy · CIK 0001737127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,430 F2 · shares: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.11 to $235.05. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 21:15 UTC |
Ban RandyChief Commercial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001104659-22-124890 · tm2232063d1_4seq1.xml · derivative · entry 10 Ban Randy · CIK 0001737127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,090 Underlying: Common Stock · 5,000 shares Expires 2027-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.